布地格福与布地奈德福莫特罗吸入剂治疗老年慢性阻塞性肺疾病的临床研究比较  

A comparative study of budigefu and budesonide formoterol inhalant in the treatment of chronic obstructive pulmonary disease in elderly patients

作　　者：张键 冯敏[1] 徐荣红[1] 韩为涛 杨学知 胡慧[1] Zhang Jian;Feng Min;Xu Ronghong;Han Weitao;Yang Xuezhi;Hu Hui(Department of Geriatrics,People's Hospital of Luzhou City,Luzhou,Sichuan,646099,P.R.China;Department of Hepatobiliary and Pancreatic Surgery,Chengdu 363 Hospital Affiliated to Southwest Medical University,Chengdu,Sichuan,610097,P.R.China)

机构地区：[1]泸州市人民医院老年病科,四川泸州646099 [2]西南医科大学附属成都三六三医院肝胆胰外科,四川成都610097

出　　处：《老年医学与保健》2024年第3期739-744,共6页Geriatrics & Health Care

基　　金：四川省卫生信息学会科研课题(2022036)。

摘　　要：目的探究布地格福和布地奈德福莫特罗吸入剂对老年中重度慢性阻塞性肺疾病(COPD)患者疗效及对血清炎症因子水平的影响。方法回顾性分析2023年1月—2023年5月于泸州市人民医院收治的中重度老年COPD患者临床资料,患者均予以稳定期COPD治疗方案,依据治疗用药不同,将采用布地格福吸入气雾剂治疗的患者设为布地格福组,采用布地奈德福莫特罗粉吸入剂治疗的患者设为布地奈德福莫特罗组,经倾向性评分匹配排除性别、年龄混杂因素,每组纳入48例,均持续治疗3个月。观察2组临床疗效,比较2组治疗前后肺通气功能指标值[用力呼气容积(FEV_(1))、用力肺活量(FVC)和FEV_(1)/FVC]、运动耐力(6MWD)、慢阻肺评估测试(CAT)、Borg呼吸困难评分、血气指标值[动脉血氧饱和度(SaO_(2))、动脉血二氧化碳分压(PaCO_(2))和动脉血氧分压(PaO_(2))]和外周炎症指标值[白细胞计数(WBC)、C反应蛋白(CRP)、血清淀粉样蛋白A(SAA)及嗜酸性粒细胞绝对值(EOS)]变化;对比治疗期间不良反应。结果治疗后,布地格福组治疗总有效率高于布地奈德福莫特罗组(95.83%vs 83.33%,P<0.05);2组FEV_(1)、FCV和FEV_(1)/FVC水平均升高(P<0.05),6MWD升高(P<0.05),CAT和Borg评分降低(P<0.05),PaO_(2)、SaO_(2)值均升高(P<0.05),PaCO_(2)值降低(P<0.05),WBC、CRP、SAA和EOS水平均降低(P<0.05),且布地格福组上述所有指标变化有统计学意义(P<0.05);2组不良反应发生率差异无统计学意义(P>0.05)。结论相对于布地奈德福莫特罗吸入剂,布地格福气雾吸入剂在老年中重度COPD患者中表现出更为显著的效果,明显改善肺通气功能、增强运动耐力及降低炎症反应,具有一定的临床应用价值。Objective To explore the therapeutic effects of budigefu and budesonide formoterol inhalant on elderly patients with moderate to severe chronic obstructive pulmonary disease(COPD)and their impact on serum inflammatory factors level.Methods The clinical data of elderly patients with moderate to severe COPD admitted to People's Hospital of Luzhou City from January 2023 to May 2023 were retrospectively analyzed.All patients were treated with a stable COPD treatment plan.Patients treated with budigefu inhalation aerosol were assigned to budigefu group and patients treated with budesonide formoterol powder inhalant were assigned to budesonide formoterol group according to different therapeutic drugs.Gender and age confounding factors were excluded by propensity score matching.48 cases were included in each group,and both groups received continuous treatment for 3 months.The clinical effect of both groups was observed.The pulmonary ventilation function indexes[forced expiratory volume(FEV_(1)),forced vital capacity(FVC)and FEV_(1)/FVC],exercise endurance(6MWD),COPD assessment test(CAT),Borg dyspnea score,blood gas indexes[arterial oxygen saturation(SaO_(2)),arterial partial pressure of carbon dioxide(PaCO_(2)),arterial partial oxygen pressure(PaO_(2))]and peripheral inflammatory markers[white blood cell count(WBC),C-reactive protein(CRP),serum amyloid A(SAA)and eosinophil absolute value(EOS)]before and after treatment were compared between the two groups.The adverse reactions during treatment were compared between the two groups.Results After treatment,the total effective rate of treatment in the budigefu group was higher than that in the budesonide formoterol group(95.83%vs 83.33%)(P<0.05).After treatment,the levels of FEV_(1),FCV and FEV_(1)/FVC in both groups increased(P<0.05),6MWD increased(P<0.05),CAT score and Borg score decreased(P<0.05),PaO_(2) and SaO_(2) values increased(P<0.05),PaCO_(2) values decreased(P<0.05),the levels of WBC,CRP,SAA and EOS decreased(P<0.05).But the above changes in the Budigefu group we

关 键 词：老年 慢性阻塞性肺疾病 布地格福气雾吸入剂 布地奈德福莫特罗吸入剂 临床疗效 

分 类 号：R563.9[医药卫生—呼吸系统]